» Articles » PMID: 26240138

MicroRNAs in the Myocyte Enhancer Factor 2 (MEF2)-regulated Gtl2-Dio3 Noncoding RNA Locus Promote Cardiomyocyte Proliferation by Targeting the Transcriptional Coactivator Cited2

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2015 Aug 5
PMID 26240138
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Understanding cell cycle regulation in postmitotic cardiomyocytes may lead to new therapeutic approaches to regenerate damaged cardiac tissue. We have demonstrated previously that microRNAs encoded by the Gtl2-Dio3 noncoding RNA locus function downstream of the MEF2A transcription factor in skeletal muscle regeneration. We have also reported expression of these miRNAs in the heart. Here we investigated the role of two Gtl2-Dio3 miRNAs, miR-410 and miR-495, in cardiac muscle. Overexpression of miR-410 and miR-495 robustly stimulated cardiomyocyte DNA synthesis and proliferation. Interestingly, unlike our findings in skeletal muscle, these miRNAs did not modulate the activity of the WNT signaling pathway. Instead, these miRNAs targeted Cited2, a coactivator required for proper cardiac development. Consistent with miR-410 and miR-495 overexpression, siRNA knockdown of Cited2 in neonatal cardiomyocytes resulted in robust proliferation. This phenotype was associated with reduced expression of Cdkn1c/p57/Kip2, a cell cycle inhibitor, and increased expression of VEGFA, a growth factor with proliferation-promoting effects. Therefore, miR-410 and miR-495 are among a growing number of miRNAs that have the ability to potently stimulate neonatal cardiomyocyte proliferation.

Citing Articles

LncRNAs in the Domain Are Essential for Mid-Embryonic Heart Development.

Teng X, He H, Yu H, Zhang X, Xing J, Shen J Int J Mol Sci. 2024; 25(15).

PMID: 39125754 PMC: 11311489. DOI: 10.3390/ijms25158184.


Upregulation of LncRNA UCA1 promotes cardiomyocyte proliferation by inhibiting the miR-128/SUZ12/P27 pathway.

Huang K, Huang D, Li Q, Zhong J, Zhou Y, Zhong Z Heliyon. 2024; 10(14):e34181.

PMID: 39100475 PMC: 11296037. DOI: 10.1016/j.heliyon.2024.e34181.


An intronic SNP affects skeletal muscle development by regulating the expression of .

Chen Y, Wang Z, Qu X, Song B, Tang Y, Li B Front Vet Sci. 2024; 11:1396766.

PMID: 38933706 PMC: 11199888. DOI: 10.3389/fvets.2024.1396766.


Cited2 inhibited hypoxia-induced proliferation and migration of PASMCs via the TGF-β1/Cited2/PPARγ pathway.

Wang H, Ma L, Yu Q Iran J Basic Med Sci. 2024; 27(4):509-517.

PMID: 38419888 PMC: 10897560. DOI: 10.22038/IJBMS.2023.74455.16178.


miRNAs Epigenetic Tuning of Wall Remodeling in the Early Phase after Myocardial Infarction: A Novel Epidrug Approach.

Salvatori F, DAversa E, Serino M, Singh A, Secchiero P, Zauli G Int J Mol Sci. 2023; 24(17).

PMID: 37686073 PMC: 10487654. DOI: 10.3390/ijms241713268.


References
1.
Liu N, Williams A, Kim Y, McAnally J, Bezprozvannaya S, Sutherland L . An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci U S A. 2007; 104(52):20844-9. PMC: 2409229. DOI: 10.1073/pnas.0710558105. View

2.
Jonckheere N, Fauquette V, Stechly L, Saint-Laurent N, Aubert S, Susini C . Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression. Br J Cancer. 2009; 101(4):637-44. PMC: 2736821. DOI: 10.1038/sj.bjc.6605190. View

3.
Naya F, Wu C, Richardson J, Overbeek P, Olson E . Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development. 1999; 126(10):2045-52. DOI: 10.1242/dev.126.10.2045. View

4.
Waerner T, Gardellin P, Pfizenmaier K, Weith A, KRAUT N . Human RERE is localized to nuclear promyelocytic leukemia oncogenic domains and enhances apoptosis. Cell Growth Differ. 2001; 12(4):201-10. View

5.
Hwang-Verslues W, Chang P, Wei P, Yang C, Huang C, Kuo W . miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene. 2011; 30(21):2463-74. DOI: 10.1038/onc.2010.618. View